Evidence map›Paper›PMID 19737947›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009

Biomarkers in GIST: partly ready for prime-time use.

Charles D Blanke

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Charles D BlankeUniversity of British Columbia and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. cblanke@bccancer.bc.ca

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use.

Indexed as

Antineoplastic AgentsBiomarkers, TumorDisease ProgressionGastrointestinal Stromal TumorsHumansIndolesPredictive Value of TestsProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrrolesSunitinibTime FactorsAntineoplastic AgentsBiomarkers, TumorIndolesProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrrolesSunitinib

Identifiers

PMID19737947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.